Last reviewed · How we verify
Oxybutinin Extended-Release
Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.
Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.
At a glance
| Generic name | Oxybutinin Extended-Release |
|---|---|
| Also known as | Lyrinel |
| Sponsor | Janssen-Cilag Ltd.,Thailand |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptor (M3) |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
By antagonizing M3 muscarinic receptors on detrusor muscle, oxybutynin decreases the frequency and amplitude of bladder contractions. The extended-release formulation provides sustained drug delivery over 24 hours, improving tolerability and compliance compared to immediate-release formulations. This mechanism reduces urinary urgency, frequency, and incontinence episodes in patients with overactive bladder.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
- Neurogenic detrusor overactivity in spinal cord injury patients
Common side effects
- Dry mouth
- Constipation
- Dizziness
- Blurred vision
- Headache
- Somnolence
Key clinical trials
- A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition (PHASE3)
- Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybutinin Extended-Release CI brief — competitive landscape report
- Oxybutinin Extended-Release updates RSS · CI watch RSS
- Janssen-Cilag Ltd.,Thailand portfolio CI